Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

EDIT

Editas Medicine Inc

Feb 13 • 04:00PM ET

1.76

+0.08 4.76 %

Healthcare • Biotechnology • USA • NASD

Peers: CRSP NTLA BEAM BLUE SGMO VERV RARE PSTX CLLS QURE

| Held by: VTI IWM VXF IWN IBB VTWO SCHA VHT IWC DFAT

Index	RUT	P/E	-	EPS (ttm)	-2.38	Insider Own	0.51%	Shs Outstand	97.62M	Perf Week	-3.30%
Market Cap	171.81M	Forward P/E	-	EPS next Y	-1.12	Insider Trans	-2.65%	Shs Float	97.12M	Perf Month	-20.72%
Enterprise Value	84.88M	PEG	-	EPS next Q	-0.23	Inst Own	50.58%	Short Float	11.80%	Perf Quarter	-34.81%
Income	-199.84M	P/S	3.70	EPS this Y	31.31%	Inst Trans	7.98%	Short Ratio	6.71	Perf Half Y	-40.54%
Sales	46.38M	P/B	12.20	EPS next Y	43.21%	ROA	-75.51%	Short Interest	11.46M	Perf YTD	-14.15%
Book/sh	0.14	P/C	1.04	EPS next 5Y	28.82%	ROE	-211.37%	52W High	4.54 -61.21%	Perf Year	43.09%
Cash/sh	1.70	P/FCF	-	EPS past 3/5Y	-0.38% -1.48%	ROIC	-246.45%	52W Low	0.91 93.39%	Perf 3Y	-82.38%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	8.15% 9.50%	Gross Margin	87.38%	Volatility	6.41% 7.50%	Perf 5Y	-96.96%
Dividend TTM	-	EV/Sales	1.83	EPS Y/Y TTM	7.19%	Oper. Margin	-258.03%	ATR (14)	0.14	Perf 10Y	-88.57%
Dividend Ex-Date	-	Quick Ratio	2.86	Sales Y/Y TTM	-24.90%	Profit Margin	-430.84%	RSI (14)	39.56	Recom	2.29
Dividend Gr. 3/5Y	- -	Current Ratio	2.86	EPS Q/Q	62.99%	SMA20	-10.42%	Beta	2.20	Target Price	5.12
Payout	-	Debt/Eq	5.85	Sales Q/Q	12265.57%	SMA50	-17.94%	Rel Volume	0.77	Prev Close	1.68
Employees	246	LT Debt/Eq	5.03	Earnings	Nov 10 BMO	SMA200	-29.49%	Avg Volume	1.71M	Price	1.76
IPO	Feb 03, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	5.44% 52.61%	Trades		Volume	1,330,213	Change	4.76%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-28-25	Initiated	H.C. Wainwright	Buy	$3
Dec-16-24	Downgrade	JP Morgan	Neutral → Underweight
Dec-13-24	Downgrade	Truist	Buy → Hold
Dec-13-24	Downgrade	Stifel	Buy → Hold	$11 → $3
Dec-13-24	Downgrade	Chardan Capital Markets	Buy → Neutral
Dec-11-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$7 → $4
Nov-25-24	Downgrade	BofA Securities	Buy → Underperform	$13 → $1
Nov-06-24	Upgrade	Evercore ISI	In-line → Outperform
Nov-04-24	Downgrade	Raymond James	Outperform → Mkt Perform
Aug-08-24	Upgrade	BofA Securities	Neutral → Buy	$13 → $15
May-09-24	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$7
Oct-24-23	Upgrade	Citigroup	Neutral → Buy	$11
Oct-18-23	Upgrade	JP Morgan	Underweight → Neutral	$8
Oct-17-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-29-23	Upgrade	Stifel	Hold → Buy	$9 → $17
Jun-12-23	Upgrade	Raymond James	Mkt Perform → Outperform	$17
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight	$15
Dec-13-22	Initiated	Citigroup	Neutral	$11
Dec-06-22	Resumed	Credit Suisse	Neutral	$13
Nov-18-22	Downgrade	Oppenheimer	Outperform → Perform	$28 → $12

Show Previous Ratings

Dec-10-25 11:30AM	Editas (EDIT) Down 8.3% Since Last Earnings Report: Can It Rebound? (Zacks) +6.56%
Nov-25-25 11:10AM	NVO Stock Down as Rybelsus Misses Goals in 2 Alzheimer's Studies (Zacks)
10:43AM	Biogen Inks Research Deal With Dayra to Boost Immunology Pipeline (Zacks)
Nov-21-25 10:15AM	AZN Wins FDA Nod for Expanded Use of Rare Disease Drug, Koselugo (Zacks)
Nov-20-25 11:38AM	COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know (Zacks)
08:48AM	Loading…
Nov-18-25 08:48AM	Top 3 Genomics Stocks to Consider for Your Portfolio (Zacks)
Nov-14-25 09:40AM	Is Alto Neuroscience, Inc. (ANRO) Outperforming Other Medical Stocks This Year? (Zacks)
Nov-11-25 10:37AM	Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y (Zacks) +5.56%
Nov-10-25 08:25AM	Editas Medicine (EDIT) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
07:24AM	Editas: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Editas Medicine Announces Third Quarter 2025 Results and Business Updates (GlobeNewswire)
Nov-07-25 07:10AM	Gyre Therapeutics, Inc. (GYRE) Q3 Earnings Surpass Estimates (Zacks) -8.18%
Nov-06-25 06:10PM	Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Nov-03-25 09:00AM	Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025 (GlobeNewswire)
Oct-30-25 05:15PM	Gilead Sciences (GILD) Q3 Earnings and Revenues Top Estimates (Zacks)
11:01AM	Loading…
Oct-09-25 11:01AM	Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress (GlobeNewswire)
Oct-06-25 09:00AM	Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences (GlobeNewswire)
Sep-29-25 12:56AM	Editas Medicine Inc. (EDIT) Confirms EDT-401 as Lead Vivo Program (Insider Monkey) +8.64%
Sep-25-25 09:15AM	Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus (PR Newswire)
Sep-11-25 11:30AM	Why Is Editas (EDIT) Down 16.9% Since Last Earnings Report? (Zacks) +5.86%
Sep-03-25 09:49AM	Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol (Zacks)
Sep-02-25 07:00AM	Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate (GlobeNewswire)
Aug-28-25 04:01PM	Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate (GlobeNewswire)
Aug-27-25 09:00AM	Editas Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-15-25 07:50AM	Why Editas Medicine Stock Was Skyrocketing This Week (Motley Fool)
Aug-13-25 07:30AM	[Latest] Global AI in Synthetic Biology Market Size/Share Worth USD 192.95 Billion by 2034 at a 28.63% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) (GlobeNewswire) +34.50%
Aug-12-25 05:15PM	Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:14PM	Editas: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Editas Medicine Announces Second Quarter 2025 Results and Business Updates (GlobeNewswire)
03:00PM	TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
10:00AM	Loading…
10:00AM	Can This Beaten-Down Stock Bounce Back? (Motley Fool)
Aug-11-25 08:15AM	Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Jul-31-25 09:40AM	Are Medical Stocks Lagging Editas Medicine (EDIT) This Year? (Zacks)
Jul-30-25 05:40PM	MiMedx (MDXG) Q2 Earnings and Revenues Beat Estimates (Zacks)
09:44AM	3 Genomics Stocks Worth Adding to Your Portfolio in 2025 (Zacks)
Jul-03-25 09:09AM	Editas Surpasses Therapeutic Gene Editing Threshold in New Preclinical Data (Insider Monkey)
Jun-28-25 05:04AM	Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now? (Motley Fool)
Jun-27-25 08:15AM	2 Beaten-Down Stocks to Avoid (Motley Fool) +7.55%
Jun-17-25 10:07AM	Editas Medicine Is Great. Here's Why You Shouldn't Buy It. (Motley Fool)
Jun-12-25 02:01AM	Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June (GlobeNewswire) +7.39%
Jun-11-25 11:30AM	Why Is Editas (EDIT) Up 40% Since Last Earnings Report? (Zacks)
May-25-25 06:00AM	1 Stock Down 97% That Could Double, According to Wall Street (Motley Fool)
May-15-25 07:30PM	Editas Medicine: A Cautionary Tale for Investors (Motley Fool) +8.24%
03:11AM	A new CFO tasked with taking scrappy Editas from last years layoffs into new gene editing territory (Pharma Voice)
May-14-25 09:31AM	Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June (GlobeNewswire) -8.00%
09:00AM	EXEL Q1 Earnings Beat, 2025 Sales View Up as Cabometyx Drives Top Line (Zacks)
07:01AM	Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire)
May-13-25 09:40AM	Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year? (Zacks)
08:42AM	Editas Q1 Loss Narrower Than Expected, Revenues Increase Y/Y (Zacks)
07:01AM	Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire)
May-12-25 05:45PM	Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +6.21%
04:48PM	Editas: Q1 Earnings Snapshot (Associated Press Finance)
04:30PM	Editas Medicine Announces First Quarter 2025 Results and Business Updates (GlobeNewswire)
04:01PM	Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board (GlobeNewswire)
12:00PM	Editas (EDIT) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
May-05-25 04:01PM	Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May (GlobeNewswire) -6.10% -13.64%
04:44AM	CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts (Seeking Alpha)
Apr-28-25 04:31PM	Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire)
Apr-04-25 11:30AM	Why Is Editas (EDIT) Down 37.1% Since Last Earnings Report? (Zacks) -8.04%
Apr-03-25 10:48AM	Editas Medicine: Do The Risks Outweigh The Rewards? (Seeking Alpha) -5.08%
Mar-21-25 08:15AM	AstraZeneca deepens China investment; Editas loses CFO to Dyne (BioPharma Dive)
Mar-20-25 04:12PM	Editas Medicine promotes Amy Parison as CFO (SeekingAlpha)
04:01PM	Editas Medicine Announces Chief Financial Officer Transition (GlobeNewswire)
Mar-05-25 05:25PM	Editas Medicine (EDIT) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +16.48% -13.17%
04:19PM	Editas: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates (GlobeNewswire)
Feb-24-25 09:00AM	Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March (GlobeNewswire)
Jan-14-25 09:30AM	Editas Medicine Outlines 2025 Strategic Priorities and Milestones (TipRanks)
Jan-13-25 09:00AM	Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities (GlobeNewswire) -7.94%
Jan-06-25 09:00AM	Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +6.72%
Dec-30-24 03:11PM	Why Is Editas Medicine, Inc. (EDIT) Among the Top CRISPR Stocks to Invest In? (Insider Monkey)
Dec-14-24 07:01AM	Editas Medicine price target lowered to $8 from $10 at Baird (TipRanks)
Dec-13-24 02:15PM	Brokerages downgrade gene editing company Editas to 'hold', shares slump 23% (Investing.com) -23.81%
01:26PM	Editas Medicine Reshapes Future with In Vivo Focus Amid Major Workforce Cuts (GuruFocus.com)
06:44AM	Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026 (Benzinga)
Dec-12-24 04:00PM	Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years (GlobeNewswire) -5.03%
12:37PM	Editas to lay off staff after search for sickle cell partner comes up empty (BioPharma Dive)
Dec-09-24 12:00PM	Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Dec-04-24 11:30AM	Why Is Editas (EDIT) Down 36.5% Since Last Earnings Report? (Zacks)
Nov-26-24 06:50AM	Editas Medicine downgraded to Underperform from Buy at BofA (TipRanks) -7.14%
Nov-06-24 09:00AM	Editas Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.13%
Nov-05-24 01:59PM	Editas Medicine Downgraded by Raymond James Amid Strategic Shift and Program Uncertainty (GuruFocus.com) +8.33%
Nov-04-24 08:40AM	Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:36AM	Editas: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Editas Medicine Announces Third Quarter 2024 Results and Business Updates (GlobeNewswire)
Oct-31-24 03:55AM	Is Editas Medicine, Inc. (EDIT) a Promising Gene Editing Stock? (Insider Monkey)
Oct-25-24 10:00AM	Earnings Preview: Editas Medicine (EDIT) Q3 Earnings Expected to Decline (Zacks)
Oct-22-24 12:13PM	Editas and Genevant team up to develop gene editing therapies (Pharmaceutical Technology) -12.50%
07:15AM	Editas, changing course again, looks to partner lead CRISPR therapy (BioPharma Dive)
07:00AM	Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update (GlobeNewswire)
Oct-21-24 04:30PM	Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics (GlobeNewswire) +11.90%
Oct-18-24 04:01PM	Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept (GlobeNewswire)
Oct-17-24 05:01PM	State Street Corp's Strategic Reduction in Editas Medicine Inc Holdings (GuruFocus.com)
Oct-05-24 06:27AM	Editas Medicine Secures $57M Deal for Gene-Editing Technology (TipRanks)
Oct-04-24 07:13PM	Editas trades part of Vertex CRISPR therapy licencing rights deal for $57m (Pharmaceutical Technology) +5.62% -5.03%
07:33AM	Editas trades Vertex fees for upfront cash in DRI deal (BioPharma Dive)
Oct-03-24 06:00PM	Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust (GlobeNewswire)
Sep-06-24 11:31AM	Editas (EDIT) Down 17% Since Last Earnings Report: Can It Rebound? (Zacks)
Aug-28-24 09:00AM	Editas Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-08-24 09:33AM	Editas (EDIT) Q2 Earnings & Revenues Miss Estimates, Stock Down (Zacks)

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Burkly Linda	EVP, CHIEF SCIENTIFIC OFFICER	Dec 03 '25	Sale	2.15	713	1,535	68,777	Dec 04 04:39 PM
O'Neill Gilmore Neil	CEO	Dec 03 '25	Sale	2.15	5,603	12,064	269,087	Dec 04 04:38 PM
Parison Amy	SVP, Chief Financial Officer	Dec 03 '25	Sale	2.15	461	993	15,908	Dec 04 04:38 PM
O'Neill Gilmore Neil	Officer	Dec 03 '25	Proposed Sale	2.50	7,000	17,500		Dec 01 05:06 PM
Burkly Linda	EVP, CHIEF SCIENTIFIC OFFICER	Sep 03 '25	Sale	2.60	710	1,843	69,490	Sep 04 04:21 PM
Parison Amy	SVP, Chief Financial Officer	Sep 03 '25	Sale	2.60	458	1,189	16,369	Sep 04 04:20 PM
O'Neill Gilmore Neil	CEO	Sep 03 '25	Sale	2.60	5,592	14,517	274,690	Sep 04 04:20 PM
O'Neill Gilmore Neil	Officer	Sep 03 '25	Proposed Sale	2.73	7,000	19,110		Aug 29 04:34 PM
Burkly Linda	Officer	Sep 03 '25	Proposed Sale	2.73	800	2,184		Aug 29 04:22 PM
Parison Amy	SVP, Chief Financial Officer	Aug 07 '25	Sale	2.58	679	1,752	16,827	Aug 08 04:28 PM
Burkly Linda	EVP, CHIEF SCIENTIFIC OFFICER	Jul 31 '25	Sale	2.49	5,121	12,757	64,398	Aug 04 04:49 PM
Burkly Linda	Officer	Jul 31 '25	Proposed Sale	3.46	7,500	25,950		Jul 30 04:15 PM
Parison Amy	SVP, Chief Financial Officer	Jun 03 '25	Sale	1.72	446	769	17,506	Jun 04 06:39 PM
Burkly Linda	EVP, CHIEF SCIENTIFIC OFFICER	Jun 03 '25	Sale	1.72	726	1,252	69,519	Jun 04 06:37 PM
O'Neill Gilmore Neil	CEO	Jun 03 '25	Sale	1.72	15,192	26,196	280,282	Jun 04 06:36 PM
O'Neill Gilmore Neil	Officer	Jun 03 '25	Proposed Sale	1.87	20,000	37,400		Jun 02 05:32 PM
Lucera Erick	EVP, CHIEF FINANCIAL OFFICER	Mar 04 '25	Sale	1.71	4,109	7,030	112,720	Mar 05 04:44 PM
O'Neill Gilmore Neil	CEO	Mar 04 '25	Sale	1.71	16,632	28,452	295,474	Mar 05 04:43 PM
Burkly Linda	EVP, CHIEF SCIENTIFIC OFFICER	Mar 04 '25	Sale	1.71	2,891	4,946	70,245	Mar 05 04:41 PM
O'Neill Gilmore Neil	Officer	Mar 03 '25	Proposed Sale	1.86	35,000	65,100		Feb 28 04:40 PM
Lucera Erick	Officer	Mar 03 '25	Proposed Sale	1.86	8,000	14,880		Feb 28 04:39 PM
Burkly Linda	Officer	Mar 03 '25	Proposed Sale	1.86	6,000	11,160		Feb 28 04:35 PM

GSG iShares S&P GSCI Commodity-Indexed Trust daily Stock Chart

Category	Commodities & Metals - Diversified Commodities	Asset Type	Commodities & Metals	Tags	U.S.	Return% 1Y	9.04%	Total Holdings	20	Perf Week	-0.80%
Sponsor	Blackrock (iShares)	ETF Type		Tags	commodity	Return% 3Y	6.13%	AUM	756.14M	Perf Month	2.91%
Fund Family		Bond Type		Tags	futures	Return% 5Y	12.46%	NAV/sh		Perf Quarter	6.41%
Index	S&P GSCI Index	Average Maturity		Tags	treasuries	Return% 10Y		52W High	26.33 -6.11%	Perf Half Y	11.60%
Index Weighting		Commodity Type		Tags	-	Return% SI		52W Low	19.86 24.47%	Perf YTD	7.20%
Active/Passive		Quant Type		Tags	-	Flows% 1M	-34.16%	Volatility	1.14% 1.26%	Perf Year	8.42%
Dividend TTM	-	ESG Type		Tags	-	Flows% 3M	-35.09%	ATR (14)	0.41	Perf 3Y	18.67%
Dividend Ex-Date	-	Dividend Type		Sector/Theme		Flows% YTD	-34.90%	RSI (14)	52.05	Perf 5Y	77.59%
Dividend Gr. 3/5Y	- -	Structure Type		Region		Flows% 1Y		Beta	0.17	Perf 10Y	94.34%
Expense	0.75%	Growth/Value		SMA20	-0.58%	Flows% 3Y		Rel Volume	0.24	Prev Close	24.69
Inverse/Leveraged		Market Cap		SMA50	3.39%	Flows% 5Y		Avg Volume	883.86K	Price	24.72
IPO	Jul 21, 2006	Option/Short	Yes / Yes	SMA200	8.16%	Trades		Volume	210,281	Change	0.12%

Aug-27-25 03:00AM	A New Breed of Active Commodity Funds Is Beating Indexers. It's All About Strategy. (Barrons.com)
Jun-20-25 02:13PM	The Israel-Iran crisis shows why you need energy stocks in your 401(k) (MarketWatch)
May-07-25 03:20AM	April's Shake-Up: Commodities Crash, Managed Futures Follow (Seeking Alpha)
May-01-25 09:15AM	Major Asset Classes - April 2025 Performance Review (Seeking Alpha)
Apr-30-25 09:27AM	An Equity Bear And A Commodity Boom? (Seeking Alpha)
10:41AM	Loading…
Apr-29-25 10:41AM	Will 2025 Be The Year Of Diversification In Equities? (Seeking Alpha)
Apr-16-25 09:48AM	The U.S. Dollar Stands At A Major Crossroads - Technical Analysis (Seeking Alpha)
Apr-15-25 11:45AM	How Tariff Tensions Are Impacting The Outlook For Oil And Other Commodities (Seeking Alpha)
Apr-10-25 01:40PM	How Commodities Can Help Diversify A Portfolio During Market Volatility (Seeking Alpha)
Apr-07-25 08:45AM	Commodity Crash (Seeking Alpha)
Apr-02-25 09:50AM	Total Return Forecasts: Major Asset Classes - April 2, 2025 (Seeking Alpha)
Apr-01-25 10:52AM	Major Asset Classes: March 2025 Performance Review (Seeking Alpha)
Mar-24-25 09:35AM	Why Some Mining Stocks Are Climbing Higher And Shrugging Off Tariff Concerns (SeekingAlpha)
Aug-03-23 09:00AM	Can Investing in Commodities Boost Your Returns? The Evidence Suggests Not (The Wall Street Journal)
Sep-15-22 05:05PM	Schedule K-3 Forms Now Available for iShares S&P GSCI Commodity-Indexed Trust (GSG) Shareholders (Business Wire)
07:16AM	Loading…
Feb-14-22 07:16AM	Commodities ETF (GSG) Hits New 52-Week High (Zacks)
Jan-07-22 03:13PM	9 Assets for Protection Against Inflation and the ETFs that Track Them (Investopedia)
Feb-12-21 12:23PM	US Farmland Prices Are Rising With Commodity Revenues (Investopedia)
Dec-19-19 01:41PM	Commodities Up for a Solid 2020? ETFs to Benefit (Zacks)
Dec-16-19 11:30AM	Best & Worst Performing Commodity ETFs (ETF.com)
Nov-11-19 04:28PM	Is It the Right Time to Try Riskier ETFs? (Zacks)
May-24-19 04:09PM	Goldman Sachs says commodity prices plunging to its worst week, but it's a great buying opportunity (Yahoo Finance Video)
Mar-18-19 06:55AM	Fund Flows Are Flashing a Danger Sign Despite Rally (Investopedia)
Nov-30-18 08:00AM	Best and Worst ETFs of November (Zacks)
Nov-27-18 10:15AM	Follow Goldman With These Commodity ETFs (Zacks)
May-02-18 12:03PM	Whats behind the recent commodity rally? (Harvest Exchange)
Apr-16-18 08:38AM	Commodity ETF (GXG) Hits New 52-Week High (Zacks)
Mar-18-18 06:31PM	Want to Invest in Commodities? Here Are 4 Smart Choices (Motley Fool)
Feb-27-18 05:27PM	Commodity ETF Bets Are Not For the Long Term (Zacks)
Feb-02-18 08:05AM	E*TRADE Significantly Expands Commission-Free ETF Lineup with 80 New Additions (Business Wire)
04:47AM	Loading…
Jan-04-18 04:47AM	This left for dead investment has blitzed into the new year with a roar (MarketWatch)
Dec-30-17 12:01AM	[$$] How Investors Can Ride A Rally in Commodities (Barrons.com)
Dec-13-17 10:49AM	Follow Goldman to Invest in Commodity ETFs for 2018 (Zacks)
Dec-08-17 03:52PM	Here's Another Reason To Be Bullish On Commodities Next Year (Forbes)
Jul-19-17 11:45AM	Goldman traders are losing money by following the firm's own advice (CNBC)
Jul-16-17 10:33AM	5 Top Commodity ETFs (Motley Fool)
Jun-13-17 03:42PM	What You Can Learn From Harvard's, Stanford's And Yale's Investments (Forbes)
Jun-07-17 06:43PM	Five Ways To Protect Your Stock Portfolio (Forbes)
Jun-05-17 05:17PM	ETF Flopper: An Expensive S&P GSCI-Tracking ETF (Barrons.com)
May-12-17 04:29PM	Believing these 5 stock market myths will cost you money (MarketWatch)
Apr-24-17 04:12PM	Caterpillar earnings: Did construction sales finally bottom? (MarketWatch)
Apr-10-17 12:11AM	Why Commodity-Index Investing May Be Futile (The Wall Street Journal)
Apr-09-17 10:58PM	Why Commodity-Index Investing May Be Futile (The Wall Street Journal)
Mar-16-17 10:33PM	Robust control and managed futures (Harvest Exchange)
Mar-08-17 09:02AM	Why The Futures World Welcomes Tax Season (Harvest Exchange)
Mar-03-17 07:48AM	Alternative Links: Peak Commodity Love (Harvest Exchange)
Mar-02-17 01:04PM	ISHARES S&P GSCI COMMODITY-INDEXED TRUST Financials
Feb-28-17 08:49AM	Active Traders Are Not Giving Up on Commodities (GSG, REMX) (Investopedia)
Feb-24-17 04:04PM	ISHARES S&P GSCI COMMODITY-INDEXED TRUST Files SEC form 10-K, Annual Report
Feb-17-17 02:49PM	Food Fight: Mexico Targets American Corn In Trump 'Trade War' (Forbes)
Feb-14-17 03:36PM	5 Biggest Broad Commodity ETFs Differ In Approach (ETF.com)
Dec-13-16 04:08PM	How The Markets Are Providing The First Whiffs Of The Animal Spirits (Forbes)
Nov-07-16 03:21PM	ISHARES S&P GSCI COMMODITY-INDEXED TRUST Files SEC form 10-Q, Quarterly Report
Oct-03-16 11:07AM	Nasdaq Commodity Index: Reflecting the Global Commodity Market
Aug-16-16 01:29PM	What Are the Threats for Emerging Markets? (Market Realist)
01:29PM	Fading Risks Are Working in Favor of Emerging Markets (Market Realist)
Aug-15-16 11:07PM	A Potential Green Shoot In Wheat Prices?
Aug-08-16 03:44PM	ISHARES S&P GSCI COMMODITY-INDEXED TRUST Files SEC form 10-Q, Quarterly Report
Aug-03-16 11:43PM	Drought In Grain Prices Reaches Historic Depths
06:52AM	[$$] 4 Ways to Profit From a Coming Jump in Inflation (Barrons.com)
Jul-28-16 11:02AM	Second Half Could See Higher Revenue Visibility (Market Realist)
Jul-22-16 09:51AM	Take Profits in AK Steel (TheStreet.com)
Jul-18-16 05:31PM	How Fallen Angels Could Reward Investors (Market Realist)
Jul-11-16 09:08AM	Latin American Markets Rise as Inflation Levels Ease in Brazil
Jul-07-16 11:55AM	Jim Grant Keynote At NYSSA
Jul-04-16 06:05AM	How Can Latin America Keep Up Inclusive Growth?
Jun-28-16 08:10AM	Odey Returns Surge On Bearish Brexit Bets
Jun-24-16 09:05AM	How Will the New Alcoa Look after the Split?
Jun-21-16 12:45PM	How to Navigate Uneven Economic Growth
Jun-19-16 09:08AM	The Stock Market, Iron Ore, Bitcoin Is Silver Next For Chinese Investors?
Jun-09-16 03:06PM	George Soros Gets Back In The Game; Is Very Bearish
Jun-06-16 03:32PM	Commodity ETFs in Bull Market for First Time in Four Years
Jun-03-16 05:45PM	The Economy is A Mosaic - S&P 500 Intrinsic Value Update
May-24-16 02:19PM	Fortescue: A Lesson in Volatility for Value Investors (Yahoo Finance Contributors)
May-17-16 12:26PM	Why Are Emerging Markets in a Sweet Spot?
May-12-16 01:52PM	SALT 2016: Kyle Bass, Leon Cooperman Debate Economy, Markets
May-06-16 01:38PM	ISHARES S&P GSCI COMMODITY-INDEXED TRUST Files SEC form 10-Q, Quarterly Report
Apr-29-16 02:53PM	Commodity ETFs Are Outperforming Stocks, Bonds
Apr-19-16 10:17AM	What Economic Factors Will the UK Consider in the Brexit Decision?
Apr-18-16 02:34PM	Did Wall Street Get It Wrong about Freeport-McMoRan?
Apr-05-16 10:39AM	Rise in Commodity Prices Could Benefit Commodity Exporters
Apr-03-16 01:19PM	Hedge Fund Lowdown: More Valeant Trouble
Apr-01-16 04:04PM	Effect of Chinas Economic Transition on Consumer-Driven Model
12:02PM	Full Interview With Value Hedge Fund Moerus Capital
Mar-30-16 09:36AM	Respite for Alcoa as the Fed Lifts Sentiments Yet Again (Market Realist)
Mar-25-16 09:07AM	How the Morenci Deal Changed Freeport-McMoRans Future
Mar-23-16 04:57PM	Freeport-McMoRan Heads back to the Mines on the Feds Latest Decision
Mar-21-16 08:12AM	How to Trade Growing 'Flight to Safety' Into Bonds, Gold as Oil, Euro Gain (TheStreet)
Mar-17-16 06:30PM	Wide-Ranging Interview With GrizzlyRock Capital
Mar-16-16 02:06PM	China and the Commodity Complex
08:55AM	Wedbush: Trump Win Could Cause A 50% Market crash
Mar-15-16 02:30PM	ISHARES S&P GSCI COMMODITY-INDEXED TRUST Files SEC form 10-K, Annual Report
Mar-14-16 02:55PM	Whats Driving Freeport-McMoRan This Season?
Mar-09-16 01:55PM	What Will the Spring Season Bring for Alcoas Valuation? (Market Realist)
10:33AM	DBC Vs. GSG: Comparing Commodities ETFs (Investopedia)
Mar-06-16 08:04AM	Dolphin or SharkTime for Concern?
Mar-04-16 03:01PM	Psychology ShiftsMr. Market Has Been As Irrational As Ever
Feb-17-16 05:16PM	Saudi Arabia Is Depleting Its Foreign Exchange Reserves
05:16PM	Saudi Arabia and Irans Standoff: Big Implications for Oil Prices
Feb-01-16 02:01PM	Top Five Articles from January: Charts, Commodities, and Compound Interest

iShares S&P GSCI Commodity-Indexed Trust seeks to track the results of a fully collateralized investment in futures contracts on the S&P GSCI Total Return Index. The Trust holds long positions in index futures that have settlement values at expiration based on the level of the S&P GSCI-ER at that time, and earning interest on its non-cash Collateral Assets used to satisfy applicable margin requirements on those index futures positions. The index reflects the return of the S&P GSCI-ER, together with the return on specified U.S. Treasury securities that are deemed to have been held to collateralize a hypothetical long position in the futures contracts comprising the S&P GSCI.

open in screener | open in yahoo | open in marketwatch | open in google | open in EDGAR

EDIT

Editas Medicine Inc

GSG

iShares S&P GSCI Commodity-Indexed Trust

Upgrade your FINVIZ experience